
Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027
Aura Biosciences is positioned as a low-risk, fully funded company focusing on bel-sar treatment for early choroidal melanoma, with pivotal Phase 3 trial data expected in 2027. The company holds $323.8 million in cash as of June 2026, supporting oper...





